Increased Serpin A5 levels in the cervicovaginal fluid of HIV-1 exposed seronegatives suggest that a subtle balance between serine proteases and their inhibitors may determine susceptibility to HIV-1 infection

Virology

Volumn 458-459, Issue 1, 2014, Pages 11-21

  Van Raemdonck, Geert ^a   Zegels, Geert ^a   Coen, Edmond ^a   Vuylsteke, Bea ^b   Jennes, Wim ^b   Van Ostade, Xaveer ^a  

^a UNIVERSITY OF ANTWERP   (Belgium)

^b INSTITUTE OF TROPICAL MEDICINE   (Belgium)

Author keywords

Cervicovaginal fluid; HESN; HIV resistance; ITRAQ; Myeloblastin; Proteomics; Serpin A5

Indexed keywords

MYELOBLASTIN; SERINE PROTEINASE INHIBITOR; SERPIN A5; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INFECTION SENSITIVITY; PRIORITY JOURNAL; PROTEIN ANALYSIS; QUANTITATIVE ANALYSIS; RISK ASSESSMENT; SERODIAGNOSIS; UPREGULATION; UTERINE CERVIX CYTOLOGY;

CERVICOVAGINAL FLUID; HESN; HIV RESISTANCE; ITRAQ; MYELOBLASTIN; PROTEOMICS; SERPIN A5;

BODY FLUIDS; COTE D'IVOIRE; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENETIC PREDISPOSITION TO DISEASE; HIV INFECTIONS; HIV-1; HUMANS; PROTEIN C INHIBITOR; SERINE ENDOPEPTIDASES; SERINE PROTEASES; SEX WORKERS;

EID: 84899840430     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2014.04.015     Document Type: Article

References (106)

1. Archibald D.W., Hebert C.C., Alger L.S., Johsnon J.P. Detection of HIV-specific antibodies in saliva and cervical secretions. Vaccine Res. 1992, 1:215-219.
2. Arenzana-Seisdedos F., Parmentier M. Genetics of resistance to HIV infection: role of co-receptors and co-receptor ligands. Sem. Immunol. 2006, 18:387-403.
3. Atashili J., Poole C., Ndumbe P.M., Adimora A.A., Smith J.S. Bacterial vaginosis and HIV acquisition: a meta-analysis of published studies. AIDS 2008, 22:1493-1501.
4. Baeten J.M., Grant R. Use of antiretrovirals for HIV prevention: what do we know and what don't we know?. Curr. HIV/AIDS Rep. 2013, 10:142-151.
5. Baumgartner P., Geiger M., Zieseniss S., Malleier J., Huntington J.A., Hochrainer K., Bielek E., Stoeckelhuber M., Lauber K., Scherfeld D., Schwille P., Waldele K., Beyer K., Engelmann B. Phosphatidylethanolamine critically supports internalization of cell-penetrating protein C inhibitor. J. Cell Biol. 2007, 179:793-804.
6. Belec L., Ghys P.D., Hocini H., Nkengasong J.N., Tranchot-Diallo J., Diallo M.O., Ettiegne-Traore V., Maurice C., Becquart P., Matta M., Si-Mohamed A., Chomont N., Coulibaly I.M., Wiktor S.Z., Kazatchkine M.D. Cervicovaginal secretory antibodies to human immunodeficiency virus type 1 (HIV-1) that block viral transcytosis through tight epithelial barriers in highly exposed HIV-1-seronegative African women. J. Infect. Dis. 2001, 184:1412-1422.
7. Belec L., Gresenguet G., Dragon M.A., Meillet D., Pillot J. Detection of antibodies to human immunodeficiency virus in vaginal secretions by immunoglobulin G antibody capture enzyme-linked immunosorbent assay: application to detection of seminal antibodies after sexual intercourse. J. Clin. Microbiol. 1994, 32:1249-1255.
8. Belec L., Tevi-Benissan C., Gresenguet G., Meillet D., Pillot J. HIV-1 antibody serum negativity with vaginal secretions positivity. Lancet 1994, 343:1046-1047.
9. Benarafa C., Priebe G.P., Remold-O'Donnell E. The neutrophil serine protease inhibitor serpinb1 preserves lung defense functions in Pseudomonas aeruginosa infection. J. Exp. Med. 2007, 204:1901-1909.
10. Beyrer C., Artenstein A.W., Rugpao S., Stephens H., VanCott T.C., Robb M.L., Rinkaew M., Birx D.L., Khamboonruang C., Zimmerman P.A., Nelson K.E., Natpratan C. Epidemiologic and biologic characterization of a cohort of human immunodeficiency virus type 1 highly exposed, persistently seronegative female sex workers in northern Thailand. Chiang Mai HEPS Working Group. J. Infect. Dis. 1999, 179:59-67.
11. Biasin M., Caputo S.L., Speciale L., Colombo F., Racioppi L., Zagliani A., Ble C., Vichi F., Cianferoni L., Masci A.M., Villa M.L., Ferrante P., Mazzotta F., Clerici M. Mucosal and systemic immune activation is present in human immunodeficiency virus-exposed seronegative women. J. Infect. Dis. 2000, 182:1365-1374.
12. Broliden K. Innate molecular and anatomic mucosal barriers against HIV infection in the genital tract of HIV-exposed seronegative individuals. J. Infect. Dis 2010, 202(Suppl. 3):S351-S355.
13. Bryan C.L., Beard K.S., Pott G.B., Rahkola J., Gardner E.M., Janoff E.N., Shapiro L. HIV infection is associated with reduced serum alpha-1-antitrypsin concentrations. Clin. Invest. Med. 2010, 33:E384-E389.
14. Buhimschi C.S., Baumbusch M.A., Campbell K.H., Dulay A.T., Buhimschi I.A. Insight into innate immunity of the uterine cervix as a host defense mechanism against infection and preterm birth. Expert Rev. Obstet. Gynecol. 2008, 4:9-15.
15. Buhimschi I.A., Buhimschi C.S., Weiner C.P., Kimura T., Hamar B.D., Sfakianaki A.K., Norwitz E.R., Funai E.F., Ratner E. Proteomic but not enzyme-linked immunosorbent assay technology detects amniotic fluid monomeric calgranulins from their complexed calprotectin form. Clin. Diagn. Lab. Immunol. 2005, 12:837-844.
16. Bungum M., Giwercman A., Bungum L., Humaidan P., Rastkhani H., Giwercman Y.L. Polymorphisms in the protein C inhibitor gene in in vitro fertilization failure. Fertil. Steril. 2010, 93:277-279.
17. Burgener A., Boutilier J., Wachihi C., Kimani J., Carpenter M., Westmacott G., Cheng K., Ball T.B., Plummer F. Identification of differentially expressed proteins in the cervical mucosa of HIV-1-resistant sex workers. J. Proteome Res. 2008, 7:4446-4454.
18. Burgener A., Rahman S., Ahmad R., Lajoie J., Ramdahin S., Mesa C., Brunet S., Wachihi C., Kimani J., Fowke K., Carr S., Plummer F., Ball T.B. Comprehensive proteomic study identifies serpin and cystatin antiproteases as novel correlates of HIV-1 resistance in the cervicovaginal mucosa of female sex workers. J. Proteome Res. 2011, 10:5139-5149.
19. Burgener A., Sainsbury J., Plummer F.A., Ball T.B. Systems biology-based approaches to understand HIV-exposed uninfected women. Curr. HIV/AIDS Rep. 2010, 7:53-59.
20. Camara M., Dieye T.N., Seydi M., Diallo A.A., Fall M., Diaw P.A., Sow P.S., Mboup S., Kestens L., Jennes W. Low-level CD4+ T cell activation in HIV-exposed seronegative subjects: influence of gender and condom use. J. Infect. Dis. 2010, 201:835-842.
21. Carballada R., Esponda P. Fate and distribution of seminal plasma proteins in the genital tract of the female rat after natural mating. J. Reprod. Fertil. 1997, 109:325-335.
22. Chege D., Chai Y., Huibner S., Kain T., Wachihi C., Kimani M., Barasa S., McKinnon L.R., Muriuki F.K., Kariri A., Jaoko W., Anzala O., Kimani J., Ball T.B., Plummer F.A., Kaul R. Blunted IL17/IL22 and pro-inflammatory cytokine responses in the genital tract and blood of HIV-exposed, seronegative female sex workers in Kenya. PLoS One 2012, 7:e43670.
23. Choi R.Y., Levinson P., Guthrie B.L., Lohman-Payne B., Bosire R., Liu A.Y., Hirbod T., Kiarie J., Overbaugh J., John-Stewart G., Broliden K., Farquhar C. Cervicovaginal HIV-1-neutralizing immunoglobulin A detected among HIV-1-exposed seronegative female partners in HIV-1-discordant couples. AIDS 2012, 26:2155-2163.
24. Cohen C.R., Plummer F.A., Mugo N., Maclean I., Shen C., Bukusi E.A., Irungu E., Sinei S., Bwayo J., Brunham R.C. Increased interleukin-10 in the the endocervical secretions of women with non-ulcerative sexually transmitted diseases: a mechanism for enhanced HIV-1 transmission?. AIDS 1999, 13:327-332.
25. Cole A.M., Cole A.L. Antimicrobial polypeptides are key anti-HIV-1 effector molecules of cervicovaginal host defense. Am. J. Reprod. Immunol. 2008, 59:27-34.
26. Cutler B., Justman J. Vaginal microbicides and the prevention of HIV transmission. Lancet Infect. Dis. 2008, 8:685-697.
27. Debily M.A., Marhomy S.E., Boulanger V., Eveno E., Mariage-Samson R., Camarca A., Auffray C., Piatier-Tonneau D., Imbeaud S. A functional and regulatory network associated with PIP expression in human breast cancer. PLoS One 2009, 4:e4696.
28. Dennis G., Sherman B.T., Hosack D.A., Yang J., Gao W., Lane H.C., Lempicki R.A. DAVID: database for Annotation, Visualization, and Integrated Discovery. Genome Biol. 2003, 4:3.
29. Deraison C., Bonnart C., Lopez F., Besson C., Robinson R., Jayakumar A., Wagberg F., Brattsand M., Hachem J.P., Leonardsson G., Hovnanian A. LEKTI fragments specifically inhibit KLK5, KLK7, and KLK14 and control desquamation through a pH-dependent interaction. Mol. Biol. Cell 2007, 18:3607-3619.
30. Devito C., Hinkula J., Kaul R., Lopalco L., Bwayo J.J., Plummer F., Clerici M., Broliden K. Mucosal and plasma IgA from HIV-exposed seronegative individuals neutralize a primary HIV-1 isolate. AIDS 2000, 14:1917-1920.
31. Drannik A.G., Nag K., Yao X.D., Henrick B.M., Ball T.B., Plummer F.A., Wachihi C., Kimani J., Rosenthal K.L. Anti-HIV-1 activity of elafin depends on its nuclear localization and altered innate immune activation in female genital epithelial cells. PLoS One 2012, 7:e52738.
32. Drannik A.G., Nag K., Yao X.D., Henrick B.M., Jain S., Ball T.B., Plummer F.A., Wachihi C., Kimani J., Rosenthal K.L. Anti-HIV-1 activity of elafin is more potent than its precursor's, trappin-2, in genital epithelial cells. J. Virol. 2012, 86:4599-4610.
33. Eckert R.L., Broome A.M., Ruse M., Robinson N., Ryan D., Lee K. S100 proteins in the epidermis. J. Invest. Dermatol. 2004, 123:23-33.
34. Ehrchen J.M., Sunderkotter C., Foell D., Vogl T., Roth J. The endogenous Toll-like receptor 4 agonist S100A8/S100A9 (calprotectin) as innate amplifier of infection, autoimmunity, and cancer. J. Leukocyte Biol. 2009, 86:557-566.
35. Elias J.E., Gygi S.P. Target-decoy search strategy for increased confidence in large-scale protein identifications by mass spectrometry. Nat. Methods 2007, 4:207-214.
36. Elmaleh D.R., Brown N.V., Geiben-Lynn R. Anti-viral activity of human antithrombin III. Int. J. Mol. Med. 2005, 16:191-200.
37. Fogel S., Guittaut M., Legrand A., Monsigny M., Hebert E. The tat protein of HIV-1 induces galectin-3 expression. Glycobiology 1999, 9:383-387.
38. Ghadially H., Keynan Y., Kimani J., Kimani M., Ball T.B., Plummer F.A., Mandelboim O., Meyers A.F. Altered dendritic cell-natural killer interaction in Kenyan sex workers resistant to HIV-1 infection. AIDS 2012, 26:429-436.
39. Ghosh M., Fahey J.V., Shen Z., Lahey T., Cu-Uvin S., Wu Z., Mayer K., Wright P.F., Kappes J.C., Ochsenbauer C., Wira C.R. Anti-HIV activity in cervical-vaginal secretions from HIV-positive and -negative women correlate with innate antimicrobial levels and IgG antibodies. PLoS One 2010, 5:e11366.
40. Ghosh M., Shen Z., Fahey J.V., Cu-Uvin S., Mayer K., Wira C.R. Trappin-2/Elafin: a novel innate anti-human immunodeficiency virus-1 molecule of the human female reproductive tract. Immunology 2009, 129:207-219.
41. Ghys P.D., Belec L., Diallo M.O., Ettiegne-Traore V., Becquart P., Maurice C., Nkengasong J.N., Coulibaly I.M., Greenberg A.E., Laga M., Wiktor S.Z. Cervicovaginal anti-HIV antibodies in HIV-seronegative female sex workers in Abidjan, Cote d'Ivoire. AIDS 2000, 14:2603-2608.
42. Ghys P.D., Diallo M.O., Ettiegne-Traore V., Kale K., Tawil O., Carael M., Traore M., Mah-Bi G., De Cock K.M., Wiktor S.Z., Laga M., Greenberg A.E. Increase in condom use and decline in HIV and sexually transmitted diseases among female sex workers in Abidjan, Cote d'Ivoire, 1991-1998. AIDS 2002, 16:251-258.
43. Gray R.H., Wawer M.J., Brookmeyer R., Sewankambo N.K., Serwadda D., Wabwire-Mangen F., Lutalo T., Li X., vanCott T., Quinn T.C. Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai. Uganda Lancet 2001, 357:1149-1153.
44. Guerini F.R., Lo C.S., Gori A., Bandera A., Mazzotta F., Uglietti A., Zanzottera M., Maserati R., Clerici M. Under representation of the inhibitory KIR3DL1 molecule and the KIR3DL1+/BW4+ complex in HIV exposed seronegative individuals. J. Infect. Dis. 2011, 203:1235-1239.
45. Hashemi F.B., Mollenhauer J., Madsen L.D., Sha B.E., Nacken W., Moyer M.B., Sorg C., Spear G.T. Myeloid-related protein (MRP)-8 from cervico-vaginal secretions activates HIV replication. AIDS 2001, 15:441-449.
46. Hattan S.J., Marchese J., Khainovski N., Martin S., Juhasz P. Comparative study of [Three] LC-MALDI workflows for the analysis of complex proteomic samples. J. Proteome Res. 2005, 4:1931-1941.
47. Hirbod T., Broliden K. Mucosal immune responses in the genital tract of HIV-1-exposed uninfected women. J. Intern. Med. 2007, 262:44-58.
48. Hladik F., Hope T.J. HIV infection of the genital mucosa in women. Curr. HIV/AIDS Rep. 2009, 6:20-28.
49. Horton R.E., McLaren P.J., Fowke K., Kimani J., Ball T.B. Cohorts for the study of HIV-1-exposed but uninfected individuals: benefits and limitations. J. Infect. Dis. 2010, 202(Suppl. 3):S377-S381.
50. Huang d.W., Sherman B.T., Lempicki R.A. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat. Protoc. 2009, 4:44-57.
51. Iqbal S.M., Ball T.B., Kimani J., Kiama P., Thottingal P., Embree J.E., Fowke K.R., Plummer F.A. Elevated T cell counts and RANTES expression in the genital mucosa of HIV-1-resistant Kenyan commercial sex workers. J. Infect. Dis. 2005, 192:728-738.
52. Iqbal S.M., Ball T.B., Levinson P., Maranan L., Jaoko W., Wachihi C., Pak B.J., Podust V.N., Broliden K., Hirbod T., Kaul R., Plummer F.A. Elevated elafin/trappin-2 in the female genital tract is associated with protection against HIV acquisition. AIDS 2009, 23:1669-1677.
53. Jennes W., Sawadogo S., Koblavi-Deme S., Vuylsteke B., Maurice C., Roels T.H., Chorba T., Nkengasong J.N., Kestens L. Cellular human immunodeficiency virus (HIV)-protective factors: a comparison of HIV-exposed seronegative female sex workers and female blood donors in Abidjan, Cote d'Ivoire. J. Infect. Dis. 2003, 187:206-214.
54. Jennes W., Vuylsteke B., Borget M.Y., Traore-Ettiegne V., Maurice C., Nolan M., Nkengasong J.N., Kestens L. HIV-specific T helper responses and frequency of exposure among HIV-exposed seronegative female sex workers in Abidjan, Cote d'Ivoire. J. Infect. Dis. 2004, 189:602-610.
55. Kaul, R., Ball, T.B., Hirbod, T., 2011. Defining the genital immune correlates of protection against HIV acquisition: co-infections and other potential confounders. Sex Transm.Infect. Epub ahead of print.
56. Kaul R., Pettengell C., Sheth P.M., Sunderji S., Biringer A., MacDonald K., Walmsley S., Rebbapragada A. The genital tract immune milieu: an important determinant of HIV susceptibility and secondary transmission. J. Reprod. Immunol. 2008, 77:32-40.
57. Kazmi S.H., Naglik J.R., Sweet S.P., Evans R.W., O'Shea S., Banatvala J.E., Challacombe S.J. Comparison of human immunodeficiency virus type 1-specific inhibitory activities in saliva and other human mucosal fluids. Clin. Vaccine Immunol. 2006, 13:1111-1118.
58. Keller A., Nesvizhskii A.I., Kolker E., Aebersold R. Empirical statistical model to estimate the accuracy of peptide identifications made by MS/MS and database search. Anal. Chem. 2002, 74:5383-5392.
59. Kulkarni P.S., Butera S.T., Duerr A.C. Resistance to HIV-1 infection: lessons learned from studies of highly exposed persistently seronegative (HEPS) individuals. AIDS Rev. 2003, 5:87-103.
60. Lajoie J., Juno J., Burgener A., Rahman S., Mogk K., Wachihi C., Mwanjewe J., Plummer F.A., Kimani J., Ball T.B., Fowke K.R. A distinct cytokine and chemokine profile at the genital mucosa is associated with HIV-1 protection among HIV-exposed seronegative commercial sex workers. Mucosal Immunol 2012, 5:277-287.
61. Larget-Piet D., Rozet J.M., Gerber S., Dollfus H., Munnich A., Kaplan J. Dinucleotide repeat polymorphism at the human protein C inhibitor (PCI) locus. Hum. Mol. Gen. 1993, 2:2201.
62. Lederman M.M., Alter G., Daskalakis D.C., Rodriguez B., Sieg S.F., Hardy G., Cho M., Anthony D., Harding C., Weinberg A., Silverman R.H., Douek D.C., Margolis L., Goldstein D.B., Carrington M., Goedert J.J. Determinants of protection among HIV-exposed seronegative persons: an overview. J. Infect. Dis 2010, 202(Suppl. 3):S333-S338.
63. Lesniak W., Slomnicki L.P., Filipek A. S100A6 - new facts and features. Biochem. Biophys. Res. Commun. 2009, 390:1087-1092.
64. Levinson P., Choi R.Y., Cole A.L., Hirbod T., Rhedin S., Payne B., Guthrie B.L., Bosire R., Cole A.M., Farquhar C., Broliden K. HIV-neutralizing activity of cationic polypeptides in cervicovaginal secretions of women in HIV-serodiscordant relationships. PLoS One 2012, 7:e31996.
65. Ma G., Greenwell-Wild T., Lei K., Jin W., Swisher J., Hardegen N., Wild C.T., Wahl S.M. Secretory leukocyte protease inhibitor binds to annexin II, a cofactor for macrophage HIV-1 infection. J. Exp. Med. 2004, 200:1337-1346.
66. Malmstrom E., Morgelin M., Malmsten M., Johansson L., Norrby-Teglund A., Shannon O., Schmidtchen A., Meijers J.C., Herwald H. Protein C inhibitor-a novel antimicrobial agent. PLoS Pathog. 2009, 5:e1000698.
67. Mangan M.S., Kaiserman D., Bird P.I. The role of serpins in vertebrate immunity. Tissue Antigens 2008, 72:1-10.
68. Marmor M., Hertzmark K., Thomas S.M., Halkitis P.N., Vogler M. Resistance to HIV infection. J. Urban Health 2006, 83:5-17.
69. Martellini J.A., Cole A.L., Venkataraman N., Quinn G.A., Svoboda P., Gangrade B.K., Pohl J., Sorensen O.E., Cole A.M. Cationic polypeptides contribute to the anti-HIV-1 activity of human seminal plasma. FASEB J. 2009, 23:3609-3618.
70. Mazzoli S., Trabattoni D., Lo C.S., Piconi S., Ble C., Meacci F., Ruzzante S., Salvi A., Semplici F., Longhi R., Fusi M.L., Tofani N., Biasin M., Villa M.L., Mazzotta F., Clerici M. HIV-specific mucosal and cellular immunity in HIV-seronegative partners of HIV-seropositive individuals. Nat. Med 1997, 3:1250-1257.
71. Meyer-Hoffert U. Reddish, scaly, and itchy: how proteases and their inhibitors contribute to inflammatory skin diseases. Arch. Immunol. Ther. Exp. (Warsz.) 2009, 57:345-354.
72. Mirmonsef P., Krass L., Landay A., Spear G.T. The role of bacterial vaginosis and trichomonas in HIV transmission across the female genital tract. Curr. HIV Res. 2012, 10:202-210.
73. Miyazawa M., Lopalco L., Mazzotta F., Lo C.S., Veas F., Clerici M. The 'immunologic advantage' of HIV-exposed seronegative individuals. AIDS 2009, 23:161-175.
74. Moreau T., Baranger K., Dade S., Dallet-Choisy S., Guyot N., Zani M.L. Multifaceted roles of human elafin and secretory leukocyte proteinase inhibitor (SLPI), two serine protease inhibitors of the chelonianin family. Biochimie 2008, 90:284-295.
75. Moriuchi H., Moriuchi M., Fauci A.S. Cathepsin G, a neutrophil-derived serine protease, increases susceptibility of macrophages to acute human immunodeficiency virus type 1 infection. J. Virol. 2000, 74:6849-6855.
76. Nesvizhskii A.I., Keller A., Kolker E., Aebersold R. A statistical model for identifying proteins by tandem mass spectrometry. Anal. Chem. 2003, 75:4646-4658.
77. Ouellet M., Mercier S., Pelletier I., Bounou S., Roy J., Hirabayashi J., Sato S., Tremblay M.J. Galectin-1 acts as a soluble host factor that promotes HIV-1 infectivity through stabilization of virus attachment to host cells. J. Immunol. 2005, 174:4120-4126.
78. Pietzsch J., Hoppmann S. Human S100A12: a novel key player in inflammation?. Amino Acids 2009, 36:381-389.
79. Pillay K., Coutsoudis A., Agadzi-Naqvi A.K., Kuhn L., Coovadia H.M., Janoff E.N. Secretory leukocyte protease inhibitor in vaginal fluids and perinatal human immunodeficiency virus type 1 transmission. J. Infect. Dis. 2001, 183:653-656.
80. Prodger J.L., Hirbod T., Kigozi G., Nalugoda F., Reynolds S.J., Galiwango R., Shahabi K., Serwadda D., Wawer M.J., Gray R.H., Kaul R. Immune correlates of HIV exposure without infection in foreskins of men from Rakai, Uganda. Mucosal Immunol. 2013.
81. Radtke K.P., Greengard J.S., Fernandez J.A., Villoutreix B.O., Griffin J.H. A two-allele polymorphism in protein C inhibitor with varying frequencies in different ethnic populations. Thromb. Haemost. 1996, 75:62-69.
82. Rahman S., Rabbani R., Wachihi C., Kimani J., Plummer F.A., Ball T.B., Burgener A. Mucosal serpin A1 and A3 levels in HIV highly exposed sero-negative women are affected by the menstrual cycle and hormonal contraceptives but are independent of epidemiological confounders. Am. J. Reprod. Immunol. 2013, 69:64-72.
83. Rohan L.C., Sassi A.B. Vaginal drug delivery systems for HIV prevention. AAPS J. 2009, 11:78-87.
84. Ryckman C., Robichaud G.A., Roy J., Cantin R., Tremblay M.J., Tessier P.A. HIV-1 transcription and virus production are both accentuated by the proinflammatory myeloid-related proteins in human CD4+ T lymphocytes. J. Immunol. 2002, 169:3307-3313.
85. Sallenave J.M. Antimicrobial activity of antiproteinases. Biochem. Soc. Trans. 2002, 30:111-115.
86. Schellenberg J.J., Plummer F.A. The microbiological context of HIV resistance: vaginal microbiota and mucosal inflammation at the viral point of entry. Int. J. Inflamm. 2012, 2012:131243.
87. Shacklett B.L. Understanding the "lucky few": the conundrum of HIV-exposed, seronegative individuals. Curr. HIV/AIDS Rep. 2006, 3:26-31.
88. Shearer G., Clerici M. Historical perspective on HIV-exposed seronegative individuals: has nature done the experiment for us?. J. Infect. Dis. 2010, 202(Suppl. 3):S329-S332.
89. Shen R., Smith P.D. Mucosal correlates of protection in HIV-1-exposed sero-negative persons. Am. J. Reprod. Immunol 2014.
90. Sironi M., Biasin M., Cagliani R., Forni D., De L.M., Saulle I., Lo C.S., Mazzotta F., Macias J., Pineda J.A., Caruz A., Clerici M. A common polymorphism in TLR3 confers natural resistance to HIV-1 infection. J. Immunol. 2012, 188:818-823.
91. Soderlund J., Hirbod T., Smed-Sorensen A., Johansson U., Kimani J., Plummer F., Spetz A.L., Andersson J., Kaul R., Broliden K. Plasma and mucosal fluid from HIV type 1-infected patients but not from HIV type 1-exposed uninfected subjects prevent HIV type 1-exposed DC from infecting other target cells. AIDS Res. Hum. Retroviruses 2007, 23:101-106.
92. Suzuki K. The multi-functional serpin, protein C inhibitor: beyond thrombosis and hemostasis. J. Thromb. Haemost. 2008, 6:2017-2026.
93. Tomescu C., Abdulhaqq S., Montaner L.J. Evidence for the innate immune response as a correlate of protection in human immunodeficiency virus (HIV)-1 highly exposed seronegative subjects (HESN). Clin. Exp. Immunol. 2011, 164:158-169.
94. Trial J., Rubio J.A., Birdsall H.H., Rodriguez-Barradas M., Rossen R.D. Monocyte activation by circulating fibronectin fragments in HIV-1-infected patients. J. Immunol. 2004, 173:2190-2198.
95. Tseng C.C., Tseng C.P. Identification of a novel secretory leukocyte protease inhibitor-binding protein involved in membrane phospholipid movement. FEBS Lett. 2000, 475:232-236.
96. Turk W.J., Kimani J., Bielawny T., Wachihi C., Ball T.B., Plummer F.A., Luo M. Associations of human leukocyte antigen-G with resistance and susceptibility to HIV-1 infection in the Pumwani sex worker cohort. AIDS 2013, 27:7-15.
97. UNAIDS AIDS epidemic update may 2013. UNAIDS 2013.
98. Van de Perre P., Desgranges C., Burny A. IgM antibodies directed to HIV: the neglected issue?. AIDS Res. Hum. Retroviruses 1994, 10:517-520.
99. van der Geld Y.M., Limburg P.C., Kallenberg C.G. Proteinase 3, Wegener's autoantigen: from gene to antigen. J. Leukocyte Biol. 2001, 69:177-190.
100. Venkataraman N., Cole A.L., Svoboda P., Pohl J., Cole A.M. Cationic polypeptides are required for anti-HIV-1 activity of human vaginal fluid. J. Immunol. 2005, 175:7560-7567.
101. Wu W.W., Wang G., Baek S.J., Shen R.F. Comparative study of three proteomic quantitative methods, DIGE, cICAT, and iTRAQ, using 2D gel- or LC-MALDI TOF/TOF. J. Proteome Res. 2006, 5:651-658.
102. Yao X.D., Omange R.W., Henrick B.M., Lester R.T., Kimani J., Ball T.B., Plummer F.A., Rosenthal K.L. Acting locally: innate mucosal immunity in resistance to HIV-1 infection in Kenyan commercial sex workers. Mucosal Immunol. 2013.
103. Young, J.M., Turpin, J., Musib, R., Sharma, O.K., 2010. Outcomes of a NIAID Workshop on Understanding HIV Exposed but Seronegative (HESN) Individuals. AIDS Res. Hum. Retroviruses Epub ahead of print.
104. Zani M.L., Baranger K., Guyot N., Dallet-Choisy S., Moreau T. Protease inhibitors derived from elafin and SLPI and engineered to have enhanced specificity towards neutrophil serine proteases. Protein Sci. 2009, 18:579-594.
105. Zegels G., Van Raemdonck G.A., Coen E.P., Tjalma W.A., Van Ostade X.W. Comprehensive proteomic analysis of human cervical-vaginal fluid using colposcopy samples. Proteome Sci. 2009, 7:17.
106. Zegels G., Van Raemdonck G.A., Tjalma W.A., Van Ostade X.W. Use of cervicovaginal fluid for the identification of biomarkers for pathologies of the female genital tract. Proteome Sci. 2010, 8:63.